Citations 1
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen, Robert W., Ansell, Stephen M. , Gallamini, Andrea , Grigg, Andrew , Sureda, Anna M., Feldman, Tatyana , Özdemir, Evren , Offner, Fritz , Engley, Gerald, Fenton, Keenan , Lee, Shih-Yuan, Jolin, Hina, Gautam, Ashish , Hutchings, Martin , Connors, Joseph M. , Savage, Kerry J. , Collins, Graham P. , Sureda, Anna , Ghosh, Nilanjan , Fosså, Alexander
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7539-7539
